Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi Goes Public With Hostile Medivation Bid

Executive Summary

Following weeks of speculation, Sanofi has gone public with its hostile offer for Medivation. Analysts are all in agreement that the deal would make "strategic sense" for Sanofi, but it's likely other suitors will throw their hats into the ring.

Advertisement

Related Content

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Brandicourt Not Ready To Raise Medivation Bid Just Yet
Sanofi Earnings Emphasize Need For Medivation Buy
Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap
Brandicourt's 'Big Reveal' Falls Flat For Sanofi

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel